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Introduction
In modern society, chemicals are indispensable for everyday 
human life. Numerous chemicals are used to maintain and im-
prove the quality of life, including cosmetics, toiletries, deter-
gents, air fresheners, agrochemicals such as pesticides and fertil-
izers, disinfectants, sterilizers, preservatives and industrial sol-
vents. Chemicals are also employed in the manufacture of vari-
ous product-comprising ingredients or parts like coatings/paints, 
photo-resistant treatments, batteries, automobiles, packaging 
and many more uncountable uses. One recent report estimated 
that as many as 80000 to 120000 chemicals are currently in use 
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worldwide, with an additional 2000 chemicals newly intro-
duced each year [1,2]. In Korea, approximately 44000 chemi-
cals are known to be in use and about 300 new chemicals are 
newly marketed annually [3]. Accordingly, exposure to humans 
and the environment is unavoidable, which can be accompanied 
by adverse effects to human health and/or the environment.
The potential danger of chemical exposure and its devastating 
outcomes has been strikingly exemplified by the recent tragic acci-
dent surrounding oligo(2-(2-ethoxy)ethoxyethyl guanidine 
chloride/polyhexamethyleneguanidine, which were inadver-
tently used to sterilize humidifiers [4]. These chemicals, which 
were originally developed as carpet sterilizers, when used in hu-
midifiers, resulted in high doses via inhalational exposure and 
unanticipated lung fibrosis, which cost 701 innocent lives, 
mostly newborn babies and nursing mothers [5]. To better pro-
tect humans and the environment against exposure to toxic 
chemicals, the Act on the Registration and Evaluation of Chem-
icals (K-REACH), was enacted and has been in force since 
2015, mandating the registration of a chemical before its release 
onto the market with relevant information on human health and 
environmental hazards [6].
Act on the Registration and Evaluation of 
Chemicals: Data Requirements, Test 
Guidelines and Skyrocketing Animal Use
K-REACH is the Korean version of the European Registra-
tion, Evaluation, Authorization and Restriction of Chemicals 
(EU-REACH) regulation. K-REACH originally aimed to man-
age the risk stemming from chemical exposure by providing rel-
evant information on intrinsic hazards and guidance regarding 
safe use, such as by providing proper classification and labeling 
[7]. In this respect, it is aligned with the United Nation (UN) 
Globally Harmonized System of Classification and Labeling of 
Chemicals (GHS) [8]. The UN GHS hazard class system cate-
gorizes chemicals according to its level of health hazard as an 
axis and toxic outcomes or endpoints as another. Accordingly, 
the effects of chemicals on the respective toxic endpoints is 
evaluated to obtain safety data so the chemical can be properly 
classified. Depending on the volume or tonnage of the chemical 
used, the level and range of information required varies, as 
shown in Table 1. Notably, K-REACH does not incorporate 
many of the animal welfare provisions contained in its European 
counterpart regulation, e.g., the Article 1 requirement to pro-
Table 1. Requirement of data for Act on the Registration and Evaluation of Chemicals registration      
Field
Tonnage [no. of test]a






















  (acute toxicity-inhalation)









Repeated dose toxicity study (28 d)
 Screening for reproductive/
  developmental toxicity
Additional genotoxicity test 
  (reproductive cell and genotoxicity)




Hazard on the 
 environment
Acute toxicity on fish
Ready biodegradability
Acute daphnia 
  immobilization test
Fresh water algae growth 
  inhibition test
Biodegradation as a function of pH
Inherent biodegradability
Identification of degradation products
Chronic toxicity on fish
Chronic toxicity on preferred species 
  daphnia 
Acute toxicity on terrestrial plants
Activated sludge respiration inhibition
Adsorption/desorption
Further information on the 
  environmental fate and behavior
Chronic toxicity on terrestrial plants
Chronic toxicity testing on terrestrial 
  invertebrates
 Further information on adsorption/
  desorption depending on the 
  results of the study
Long-term toxicity to sediment 
  organisms
Bio-concentration
aTest items for lower tonnage are also required.      
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mote alternatives to animal testing, the Article 13 requirement 
to generate new data wherever possible by means other than 
vertebrate animal tests, the Article 25 requirement to avoid un-
necessary testing, and the Annex XI rules for waiving or other-
wise adapting standard data requirements [9]. According to the 
list of tests required by K-REACH shown in Table 1, for chemi-
cal substances manufactured or imported in volumes of 1000 
tons or more per year, the data package must include 46 test 
items; this entails a huge amount of money and resources. Fur-
thermore, to generate health hazard and ecotoxicology packages 
using conventional test guideline methods, the animal use 
would be astronomical. In the worst case scenario, the number 
of animals required per substance would be nearly 6000, just for 
the assessment of human health effects, at a cost of more than 
1.5 billion Korean won. The number of animals required and 
the costs for each test are listed in Table 2.
Given that about 300 chemicals are newly introduced into Ko-
rean market every year, the use of animals would be enormous 
without any drastic changes. Statistics published recently by the 
Korean Ministry of Agriculture, Food and Rural Affairs (MA-
FRA) reflects a 36.7% increase in experimental animal use between 
2012 and 2015 (2012, 1834000; 2013, 1967000; 2014, 2412000; 
2015, 2507000) [10]. This problem is not unique to Korea. Fol-
lowing the enactment of REACH in the EU, the European 
Chemicals Agency has estimated that 30000 substances will be 
registered, requiring upwards of 3.9 million animals to be used in 
tests costing €1.6 billion (US$ 2.3 billion) [11,12]. However, 
others have suggested that the European Chemicals Agency’s es-
timates may represent a substantial underestimation of both chem-
ical registrations and animal use, projecting on the order of 68000 
substance registrations and use of 54 million animals, respectively 
[13]. Thus, the European public has demanded swift action by 
authorities and industry to ensure effective sharing of existing 
data, uptake of validated alternatives to animal tests, and other 
scientifically supported replacement, reduction or refinement 
(3R) best practices. 
Limitation and Problems of 
Conventional Animal Experiments
Conventional animal experiments have been developed and 
used on the premise that the responses of animals in the labora-
tory to chemicals can provide information to predict those of 
humans in the real world. However, this basis is somewhat in-
correct with respect to species differences in genetic expression, 
absorption, distribution, metabolism and excretion, organ sus-
ceptibility, immune responses and resistance or tolerance to xe-
nobiotics. This point has been explicitly criticized by Leist and 
Hartung [14], who stated that “the human is not a 70 kg rat.” In-
deed, rats, one of the most widely exploited experimental animal 
species, have different metabolic capacity and immune respons-
es to humans, which seriously undermines the predictability of 
the experimental data [15]. Another important point which di-
minishes the utility of animal experiments is that extreme con-
ditions are generally employed as the “worst case scenario” in 
view of chemical exposure levels (extremely high doses ranging 
from 10-fold to 1000-fold higher than human exposure levels) 
[16], exposure route (forced eyelid eversion for ocular irritant 
administration and closure for persistent exposure, or injection 
into sutured oral pouches to simulate oral mucosal exposure), 
stress (unrealistically stressful conditions like cold or hot condi-
tions), or disease states (no animal naturally exhibits an asthma-
Table 2. Number of animals required for the assessment of human health effects      
Costa per substance Primary species Second species Primary species (second cohorts)
Acute toxicity for oral 2948571b 24
Acute toxicity for dermal or inhalation 3338333b 40
Skin irritation and corrosion 3186000b 3
Skin sensitization 13195000b 45
Eye irritation and corrosion 3186000b 3
Repeated dose toxicity (28 d) 78637500b 60 60
Repeated dose toxicity (90 d) 90000000c 120 100
In vivo mutagenicity/genotoxicity 9580517b 25-80
Carcinogenicity 1000000000c 500 500
Two generation 270000000c 200 240
Reproductive toxicity
Reproductive toxicity screening 62000000 -70000000c 675
Total 1540071921 5975
GLP, good laboratory practice; CRO, contract research organization.
aUnit Korean won.
b Ministry of Environment 2016 (average price of 15 GLP-CROs).      
cFrom a single GLP-CRO.     
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like syndrome that is similar to the disease in humans) [17].
Although these experimental approaches may save time (using 
a high dose to curtail the time factor) and cost, they frequently pro-
duce unrealistic and inaccurate dose-response data for the pre-
diction of human responses. Exemplifying this, endocrine dis-
rupting chemicals generally exhibit unconventional non-linear, 
bell-shaped or U-shaped dose-response patterns that cannot be 
properly evaluated in high-dose animal experiments [18]. The 
dose-limiting toxicity of drug candidates observed in animal 
tests mostly do not appear in human clinical trials and the poor 
predictability of animal experiments has been observed across 
diverse target tissues [19]. Due to the failure of clinical trials by 
the appearance of unscreened toxicity during preclinical trials, 
enormous amounts of money and time are wasted [20]. In this 
context, the development of more human-relevant and ad-
vanced methods is necessary to replace or at least to supplement 
traditional animal tests. 
In addition to the major scientific drawbacks described above, 
animal tests have been criticized for their inherent cruelty, for 
being excessively time-intensive and resource-intensive, restric-
tive in the number of substances or mixtures that can be tested, 
and of little value in understanding the mechanistic underpin-
nings of toxicity in the species of ultimate interest.
New Methods as Replacements for 
Conventional Animal Tests 
The last century has witnessed unprecedented scientific and 
technological advances in biology, represented by human whole 
genome sequencing [21], the birth of functional genomics [22], 
computational biology, and high-speed robot automation of cell-
based (in vitro) screening systems [23]. These innovations are 
being incorporated into a wide range of health and molecular/
cellular biological research sectors, providing renewed vigor and 
inspiration in these areas. Numerous novel and revolutionary 
biochemical and molecular tools have been developed thro ugh 
this innovation, including high throughput assays, quantitative real 
time-polymerase chain reaction, flow cytometry, high content as-
says, gene transfection, reporter gene assays and tissue engineer-
ing. in fact, these new tools have helped to understand how toxi-
cants disrupt the normal physiology of the human body at the 
cellular and molecular levels, which has contributed to the birth 
of molecular and mechanistic toxicology [24]. The resulting 
predictions regarding human safety and the risk of a chemical 
are potentially more relevant to people than animal tests. In line 
with this, the Toxicology for the 21st Century or “Tox21” strate-
gy has been embarked on with a grand vision “to innovate virtu-
ally all routine toxicity testing to be conducted in human cells or 
cell lines” [25]. These non-animal based new testing methods 
enable safety evaluations of a much larger number of substances, 
in a more rapid, efficient and cost-effective way. Most impor-
tantly, these methods are likely to be more relevant to toxicity in 
humans, as well as capable of identifying the cellular mecha-
nisms of toxicity using fewer or no animals [26,27]. 
Development of Non-animal Based 
Alternatives and Their Adoption by 
Regulatory Science
Safety and regulatory science is one of most conservative and 
slowest-moving sectors in taking up new and novel methods, 
since many countries with diverse cultural and socioeconomic 
backgrounds must comply with new regulation through so-called 
“international and inter-regional harmonization”. Moreover, 
there are various stakeholders with conflicting interests even 
within a single country. This is understandable, since important 
policies like drinking water standards, sewage control, emission 
limits, inclusion on positive or negative lists, and authorizing the 
use of chemicals are based upon safety evaluations and risk as-
sessments, which often cost enormous amounts of money to 
achieve compliance, with serious risks to public health or the en-
vironment in the absence of compliance. Prior to implementa-
tion, a newly developed method must be compared regarding its 
relevance and reliability to the original gold standard method or 
targeted toxicity endpoint in humans in a validation trial, which 
can take as long as 10 years from the initial research and develop-
ment steps [28]. The results of validation studies are then subject to 
regulatory adoption processes, involving appraisal by experts 
with multi-disciplinary backgrounds, often with the participation 
of more than one regulatory body from multiple countries.
International regulatory bodies or collaborative organizations 
that can represent a large number of countries, like the Organi-
zation for Economic Cooperation and Development (OECD), 
the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use and the International Organization for Standardization 
have participated in these review and appraisal processes to ac-
commodate the opinions of member countries. Of these, the 
OECD is the most active in publishing and updating new test 
guidelines (TGs), along with integrated approaches to testing 
and assessment and other guidance materials, which 35 member 
countries can follow as the standardized methods. Many in vitro 
or in vivo tests with animal replacement, reduction or refinement 
potential have been included as TGs recently, as shown in Table 3 
[29], indicating 3R concepts applied to TGs, which are classified 
according to toxic endpoints. While non-animal tests have been 
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actively developed and widely used in skin or eye irritation tests, 
the alternative tests are not yet established for acute toxicity or re-
provductive toxicity.
OECD TGs on toxicity tests were first developed in early 1980s, 










Acute toxicity 420 Acute oral toxicity: fixed dose procedure In vivo Refinement 2002 20
423 Acute oral toxicity: acute toxic class method In vivo Reduction 2002 12
425 Acute oral toxicity: up-and-down procedure In vivo Refinement/
 reduction
2008 9
Skin irritation and 
 corrosion
404 Acute dermal irritation/corrosion In vivo Refinement 2015 3-4
430 In vitro skin corrosion: transcutaneous electrical resistance test method In vitro Replacement 2015 0
431 In vitro skin corrosion: reconstructed human epidermis test method In vitro Replacement 2015 0
435 In vitro membrane barrier test method for skin corrosion In vitro Replacement 2015 0
439 In vitro skin irritation: reconstructed human epidermis test method In vitro Replacement 2015 0
Skin sensitization 429 Skin sensitization: local lymph node assay In vivo Reduction 2010 24
442A Skin sensitization: local lymph node assay: DA In vivo Refinement/
 reduction
2010 24
442B Skin sensitization: local lymph node assay: BrdU-ELISA In vivo Refinement/
 reduction
2010 24
442C In chemico skin sensitization: direct peptide reacitivity assay In vitro Replacement 2015 0
442D In vitro skin sensitization: ARE-Nrf2 luciferase test method In vitro Replacement 2015 0
442E In vitro skin sensitisation: human cell line activation test In vitro Replacement 2016 0
Eye irritation and 
 corrosion
405 Acute eye irritation/corrosion In vivo Refinement 2012 1-3
437 Bovine corneal opacity and permeability test method In vitro Replacement 2013 0
438 Isolated chicken eye test method In vitro Replacement 2013 0
460 F luorescein leakage test method for identifying ocular corrosives and 
severe irritants
In vitro Replacement 2012 0
491 S hort time exposure In vitro test method for identifying; i) chemicals 
inducing serious eye damage and ii) chemicals not requiring 
classification for eye irritation or serious eye damage
In vitro Replacement 2015 0
492 R econstructed human cornea-like epithelium test method for identifying 
chemicals not requiring classification and labelling for eye irritation or 
serious eye damage
In vitro Replacement 2015 0
Dermal/ percutaneous 
 absorption
428 Skin absorption: in vitro method In vitro Replacement 2004 0
Mutagenicity/
 genotoxicity
471 Bacterial reverse mutation test In vitro Replacement 1997 0
473 In vitro mammalian chromosomal aberration test In vitro Replacement 2014 0
474 Mammalian erythrocyte micronucleus test In vivo Refinement 2014 23-35
475 Mammalian bone marrow chromosomal aberration test In vivo Refinement 2014 45
476 In vitro mammalian cell gene mutation tests using the hprt and xprt genes In vitro Replacement 2015 0
478 Rodent dominant lethal test In vivo Refinement 2015 96-120
483 Mammalian spermatogonial chromosomal aberration test In vivo Refinement/ 
 reduction
2015 45
487 In vitro mammalian cell micronucleus test In vitro Replacement 2014 0
488 Transgenic rodent somatic and germ cell gene mutation assays In vivo Refinement 2013 25
489 In vivo mammalian alkaline comet assay In vivo Refinement/ 
 reduction
2014 25~35
490 In vitro mammalian cell gene mutation tests using the thymidine kinase gene In vitro Replacement 2015 0
Reproductive toxicity 421 Reproduction/developmental toxicity screening test In vivo Refinement/ 
 reduction
2015 90
422 C ombined repeated dose toxicity study with the reproduction/
developmental toxicity screening test
In vivo Refinement/ 
 reduction
2015 90
443 Extended one- generation reproductive toxicity study In vivo Refinement/ 
 reduction
2012 140
Photo-induced toxicity 432 In vitro 3T3 NRU phototoxicity test In vitro Replacement 2004 0
Carcinogenicity 453 Combined chronic toxicity/carcinogenicity studies In vivo Reduction 2009 560
OECD, Organization for Economic Cooperation and Development; TG, test guidelines; 3R, replacement, reduction or refinement; BrdU-ELISA, bromodeoxy-
uridine-enzyme-linked immunosorbent assay; ARE-Nrf2, antioxidant responsive element binded NF-E2-related factor 2; DA, developed by Daicel Chemical 
Industries, Ltd; NRU, neutral red uptake.
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and have been revised continuously by 3R concepts and with 
the progression of science. From the 1980s to the early 2000s, 
mainly in vivo methods using animals were adopted as TGs, and 
the pace of development or the appearance of new methods was 
slow. However, since the late 2000s, the TGs have been annually 
revised with 3R concepts, and many new alternative animal tests 
have been adopted (Table 3), and many old or obsolete TGs 
can now be abandoned. The number of TG revisions by year is 
shown in Figure 1 [27].
Human biology-based in vitro methods are typically more rel-
evant and predictive, less time-consuming, can accommodate 
larger number of chemicals or mixtures than traditional animal 



























































































































































Figure 1. Number of revision or updates of Organization for Economic 
Cooperation and Development test guideline by Dec 2015.
Table 4. Category and tools employed for OECD TGs based on non-animal based methodology       
Category OECD TG No. Toxi endpoints Title System and tools employed
Ex vivo 437 Eye irritation/corrosion B ovine corneal opacity and permeability test 
method
Is olated corneas from the eyes of cattle 
slaughtered (UV absorbance/Opacimeter)
438 Eye irritation/corrosion Isolated chicken eye test method Eyes of slaughtered chicken 
 (slit-lamp microscopes)
460 Eye irritation/corrosion F luorescein Leakage test method for identifying 
ocular corrosives and severe irritants
C onfluent monolayer of Madin-Darby canine 
kidney (UV absorbance)
In vitro 430 Skin corrosion In vitro skin corrosion: transcutaneous electrical 
resistance test method 
Rat skin disk (voltohmmeter)
431 Skin corrosion In vitro skin corrosion: reconstructed human 
epidermis test method
Reconstructed human epidermis 
 (3D tissue engineering)
435 Skin corrosion In vitro membrane barrier test method for skin 
corrosion
Artificial membrane
439 Skin irritation In vitro skin irritation: reconstructed human 
epidermis test method
Reconstructed human epidermis 
 (3D tissue engineering)
442D Skin sensitization In vitro skin sensitization: ARE-Nrf2 luciferase 
test method
C ell line which contains the luciferase gene 
under the transcriptional control of a 
constitutive promoter fused with an are element 
(reporter gene assay)
442E     Skin sensitization In vitro skin sensitisation: human cell line 
activation test
Human monocytic leukaemia cell line THP-1
491 Eye irritation/corrosion S hort time exposure in vitro test method for 
identifying i) chemicals inducing serious eye 
damage and ii) chemicals not requiring 
classification for eye irritation or serious eye 
damage
Statens seruminstitut rabbit cornea cells
492 Eye irritation/corrosion R econstructed human cornea-like epithelium test 
method for identifying chemicals not requiring 
classification and labelling for eye irritation or 
serious eye damage
Reconstructed human cornea-like epithelium 
 (3D tissue engineering)
428 Dermal/percutaneous absorption Skin absorption: in vitro method Viable or non-viable human (animal) skin
471 Mutagenicity/genotoxicity Bacterial reverse mutation test Salmonella typhimurium, escherichia coli
473 Mutagenicity/genotoxicity In vitro mammalian chromosomal aberration test Mammalian somatic cells
476 Mutagenicity/genotoxicity In vitro mammalian cell gene mutation tests 
using the HPRT and XPRT genes
Mammalian cells (ex. cho, chl)
487 Mutagenicity/genotoxicity In vitro mammalian cell micronucleus test Mammalian cells (ex. blood lymphocytes)
490 Mutagenicity/genotoxicity In vitro mammalian cell gene mutation tests 
using the thymidine kinase gene
L 5178Y tk+/-3.7.2C cells for the mouse 
lymphoma assay, TK6 tk+/- cells for the TK6 
assay
432 Photo-cytotoxicity In vitro 3T3 NRU phototoxicity test Balb/c 3T3 cells
In chemico 442C Skin sensitization In chemico skin sensitization: direct peptide 
reactivity assay
Synthetic peptides (LC/UV)
OECD, Organization for Economic Cooperation and Development; TG, test guideline; UV, ultraviolet; 3D, three-dimensional; HPRT, hypoxanthine-guanine phosphoribo-
syl transferase; XPRT, xanthine phosphoribosyl transferase; NRU, neutral red uptake; LC, liquid chromatography.
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the framework of an adverse outcome pathway (AOP). By sys-
temically categorizing the biological events leading to adverse 
effects into key events between two points, i.e., a molecular initi-
ating event and an adverse outcome, the AOP describes an ad-
verse outcome following exposure to a chemical by a series of 
key events and key event relationships that describe the causal rela-
tionships between the key events. AOPs are instrumental for es-
tablishing the toxic mechanism of an adverse outcome and the 
utilization of safety test data at the in vitro, in vivo and human 
levels for risk assessments and regulatory applications. In the 
best case scenario, the number of animals saved by employing 
multiple in vitro tests along with limited in vivo tests will be in 
the thousands, which will significantly contribute to animal eth-
ics without compromising predictive capacity or risking human 
health or environmental protection.
Pros and Cons of In Vitro Alternatives to 
Animal Tests 
Ultimately and ideally, all animal experiments, including those 
with refined or reduced use of animals, are to be changed into 
non-animal based methods. These methods can be largely cate-
gorized into in chemico, ex vivo and in vitro methods. Approved 
OECD TGs fall into these categories, as shown in Table 4.
Since these methods largely employ test-tube or multi-well 
plate formats, the throughput is much higher than traditional 
animal experiments. For example, the 3D reconstructed human 
cornea-like epithelium (RhCE) method can evaluate the ocular 
irritancy of 10 test substances in one run, which takes three days 
from the delivery of the model [28]. This test is equivalent to 10 
tests using the in vivo Draize rabbit eye irritation test, costing the 
lives 30 of rabbits and taking at least 10 days from the delivery of 
the rabbits [30]. This test can be harnessed to assess multiple 
combinations of test conditions like different mixture ratios, di-
verse exposure scenarios and the addition of metabolic capacity 
using a feasible amount of time and money [27]. Moreover, 
through targeting a single molecular event on the AOP frame-
work, the conclusions of alternative methods may be more di-
rect and straightforward, which is critical to address the mecha-
nism of toxicity and extrapolation into human responses. For 
example, in the direct peptide reactivity assay, an in chemico skin 
sensitization test that addresses the haptenization response of a 
substance, positive results indicate that the chemical is reactive 
and can form protein adducts [31]. 
Of course, there are limitations and shortcomings of non-ani-
mal methods as well. First, most of the alternatives have not ad-
vanced into the level of risk assessment, since they only give a 
qualitative “yes” or “no” answer, namely hazard identification. 
Even though some methods give quantitative data, their utility 
for potency classification or risk assessment has not been fully 
validated [32]. In addition, since the alternatives address mostly 
a single key event in the series of events constituting a larger 
AOP, they cannot provide the full mechanistic information re-
garding the final outcome of the initial exposure [33]. In this 
case, a combination of multiple in vitro assays can be used as an 
integrated approach to testing and assessment (IATA) [34]. In-
deed, considerable efforts have been directed toward developing 
a standardized IATA scheme. 
Barriers to Acceptance of Non-animal 
Based Alternatives in Act on the 
Registration and Evaluation of Chemicals 
and Recommendations
Although many validated and internationally recognized non-
animal methods and strategies are now available and ready for 
immediate use in regulatory frameworks such as K-REACH, 
their uptake by Korean authorities continues to be less than op-
timal. Whereas EU-REACH data requirements and guidance 
have been or are being amended to incorporate all available 
OECD 3R TGs and related best practices, such is not yet the 
case with K-REACH [35,36]. This is in part due to the lack of a 
“mandatory 3R” requirement under K-REACH and other legis-
lation for the uptake of new methods. In addition, there is a lack 
of inter-ministerial cooperation regarding the uptake of new meth-
ods. For example, the Korean Centre for the Validation of Alter-
native Methods has been established under the Ministry of 
Food and Drug Safety (MFDS), but does not currently include 
participation from other regulatory or research agencies in the 
development, validation or regulatory review of non-animal 
based methods [37], indicating the inter-ministerial inefficiency 
and passive attitudes towards new and more advanced methods. 
Delayed implementation of 3R-based alternatives, due to these 
inefficiencies, would lead to the unnecessary sacrifice of labora-
tory animals, even though they are not better than new alterna-
tives for the protection of human health and the environment. 
There are also duplicate experiments for substances that have al-
ready been tested and assigned GHS classifications, including 
chemicals that are known corrosives, fatal if inhaled or probable 
carcinogens. The scientific basis for duplicating well-established 
test results and regulatory classifications is incomprehensible, par-
ticularly where vertebrate animal testing would be involved, and 
most notably where such testing (e.g., of corrosives) would result 
in the most extreme pain and suffering for the animals involved. 
To ensure that the Korean regulatory framework for chemi-
cals, and the general approach to the validation and adoption of 
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3R best practices, do not fall farther behind those of other devel-
oped nations, K-REACH data requirements and TGs must be 
immediately and frequently amended on regular basis to incor-
porate all relevant OECD 3R TGs and related best practices, in-
cluding mandatory data sharing, chemical grouping and read-
across to ensure maximum possible reduction of vertebrate ani-
mal use and no duplication of existing test results. One over-
arching regulatory body shall be formed to include all Korean 
ministries with a stake in alternative methods and safety assess-
ment, including the MFDS, the Ministry of Environment (MOE), 
and the MAFRA to facilitate inter-ministerial cooperation to-
ward the development of a comprehensive government strategy 
and funding framework for the reduction and replacement of 
animals used for toxicity testing and life sciences research [38].
Conclusion
The implementation of K-REACH will contribute to the safe 
use of chemicals by identifying human health effects and eco-
toxicity before their introduction to human society and the en-
vironment. However, a huge number of laboratory animals are 
required to comply with the current Korean guidelines, which is 
sometimes unnecessary and can be replaced with alternative 
methods. Therefore, in order for K-REACH to be more practi-
cally implemented, 3R concepts and alternative to animal tests 
(AATs) should be actively accepted, which has been advanced 
in the developed countries. Using AATs for safety assessment is 
scientific, highly reliable and predictable and may be more hu-
man-relevant without inflicting pain and death in laboratory ani-
mals. Moreover, the application of AATs may be more economi-
cal and effective than animal tests. The implementation of AATs 
is also a concern in other chemical sectors such as the food, cos-
metics, drug and agrochemical industries. In this regard, the col-
laboration of the MOE, the MFDS, and MAFRA in Korea is 
critical. Korean regulatory authorities should actively communi-
cate and collaborate to follow global trends in safety assessments 
and rapidly developing alternative tests.
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